8-KLeadership ChangesOther Events

QUEST DIAGNOSTICS INC 8-K Report, Executive Changes (Feb 9, 2011)

Filed February 9, 2011For Securities:DGX

Summary

Quest Diagnostics Incorporated (DGX) filed an 8-K on February 9, 2011, primarily addressing a waiver related to a stockholders' agreement with GlaxoSmithKline plc (GSK). The company waived certain provisions of their August 16, 1999, stockholders' agreement, which would have led to the deemed resignation of Mr. John Ziegler, a director appointed by GSK. This waiver was a direct response to GSK's complete sale of its holdings in Quest Diagnostics on February 4, 2011. By waiving these provisions, Quest Diagnostics ensured that Mr. Ziegler could continue to serve as a director, maintaining stability on the board following the significant share disposition by a major stakeholder.

Key Highlights

  • 1Quest Diagnostics waived provisions of its stockholders' agreement with GlaxoSmithKline plc (GSK).
  • 2The waiver prevented the deemed resignation of director Mr. John Ziegler.
  • 3Mr. Ziegler was originally designated as a director by GSK.
  • 4The waiver was necessary due to GSK's sale of all its common stock holdings in Quest Diagnostics.
  • 5The GSK share sale occurred on February 4, 2011.
  • 6Mr. Ziegler will continue to serve as a director of Quest Diagnostics as a result of the waiver.

Frequently Asked Questions

The main reason was Quest Diagnostics waiving certain provisions of its stockholders' agreement with GlaxoSmithKline (GSK) to allow Mr. John Ziegler, a director designated by GSK, to continue serving on the board despite GSK selling all its shares.

Under the terms of the original stockholders' agreement, GSK selling all its holdings would have triggered a provision leading to the deemed resignation of Mr. Ziegler, who was their designated director.

GSK's sale of all its common stock signifies the end of its significant investment and likely a strategic shift. The waiver was crucial to maintain board continuity and governance as this major shareholder exited its position.

While Mr. Ziegler was originally designated by GSK, his continued directorship is now a result of the waiver and not tied to GSK's shareholding. His future role will be as an independent director, no longer representing a specific shareholder bloc.